CoChat
Sign Up
Cited by 282

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

The unique properties of IgG4 and its roles in health and disease

Rispens, Theo, Huijbers, Maartje G.·2023·Nature Reviews Immunology
DOI 10.1038/s41577-023-00871-zPMC PMC10123589
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41577-023-00871-z

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Research works printed but not linked: 157

  1. Vidarsson, G., Dekkers, G. & Rispens, T. IgG subclasses and allotypes: from structure to effector functions. Front. Immunol. 5, 520 (2014). · DOI · Paper page
  2. Volkov, M. et al. Comprehensive overview of autoantibody isotype and subclass distribution. J. Allergy Clin. Immunol. 150, 999–1010 (2022). · DOI
  3. Kitaura, K. et al. Different somatic hypermutation levels among antibody subclasses disclosed by a new next-generation sequencing-based antibody repertoire analysis. Front. Immunol. 8, 389 (2017). · DOI
  4. Lighaam, L. C. & Rispens, T. The immunobiology of immunoglobulin G4. Semin. Liver Dis. 36, 200–215 (2016). · DOI
  5. Lighaam, L. C. et al. Phenotypic differences between IgG4+ and IgG1+ B cells point to distinct regulation of the IgG4 response. J. Allergy Clin. Immunol. 133, 267–270.e1–e6 (2014). This paper is the first to report the isolation and phenotyping of IgG4+ B cells. · DOI
  6. Aalberse, R. C., Stapel, S. O., Schuurman, J. & Rispens, T. Immunoglobulin G4: an odd antibody. Clin. Exp. Allergy 39, 469–477 (2009). · DOI
  7. Unger, P. A. et al. Divergent chemokine receptor expression and the consequence for human IgG4 B cell responses. Eur. J. Immunol. 50, 1113–1125 (2020). · DOI
  8. Blanco, E. et al. Age-associated distribution of normal B-cell and plasma cell subsets in peripheral blood. J. Allergy Clin. Immunol. 141, 2208–2219.e16 (2018). This study provides comprehensive quantification of absolute serum levels of antibody and numbers of B cells and plasma cells in an isotype-specific and subclass-specific manner in humans. · DOI
  9. Katz, G. & Stone, J. H. Clinical perspectives on IgG4-related disease and its classification. Annu. Rev. Med. 73, 545–562 (2022). · DOI
  10. Huijbers, M. G. et al. The expanding field of IgG4-mediated neurological autoimmune disorders. Eur. J. Neurol. 22, 1151–1161 (2015). · DOI
  11. Koneczny, I. A new classification system for IgG4 autoantibodies. Front. Immunol. 9, 97 (2018). · DOI
  12. Lepage, N., Huang, S. H., Nieuwenhuys, E. & Filler, G. Pediatric reference intervals for immunoglobulin G and its subclasses with Siemens immunonephelometric assays. Clin. Biochem. 43, 694–696 (2010). · DOI
  13. Aucouturier, P. et al. Measurement of serum IgG4 levels by a competitive immunoenzymatic assay with monoclonal antibodies. J. Immunol. Methods 74, 151–162 (1984). · DOI
  14. Unger, P. P. et al. Repeated vaccination with tetanus toxoid of plasma donors with pre-existing specific IgE transiently elevates tetanus-specific IgE but does not induce allergic symptoms. Clin. Exp. Allergy 48, 479–482 (2018). · DOI
  15. Irrgang, P. et al. Class switch toward noninflammatory, spike-specific IgG4 antibodies after repeated SARS-CoV-2 mRNA vaccination. Sci. Immunol. 8, eade2798 (2023). · DOI
  16. van der Lee, S., Sanders, E. A. M., Berbers, G. A. M. & Buisman, A. M. Whole-cell or acellular pertussis vaccination in infancy determines IgG subclass profiles to DTaP booster vaccination. Vaccine 36, 220–226 (2018). · DOI
  17. van der Neut Kolfschoten, M. et al. Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange. Science 317, 1554–1557 (2007). This study shows the therapeutic potential of IgG4 to counteract the effects of IgG1 autoantibodies to AChR in rhesus macaques. · DOI
  18. Bruhns, P. et al. Specificity and affinity of human Fcγ receptors and their polymorphic variants for human IgG subclasses. Blood 113, 3716–3725 (2009). · DOI · Paper page
  19. Sondermann, P., Huber, R., Oosthuizen, V. & Jacob, U. The 3.2-A crystal structure of the human IgG1 Fc fragment-FcγRIII complex. Nature 406, 267–273 (2000). · DOI
  20. Shields, R. L. et al. High resolution mapping of the binding site on human IgG1 for FcγRI, FcγRII, FcγRIII, and FcRn and design of IgG1 variants with improved binding to the FcγR. J. Biol. Chem. 276, 6591–6604 (2001). · DOI
  21. Bruggemann, M. et al. Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies. J. Exp. Med. 166, 1351–1361 (1987). · DOI
  22. Steplewski, Z. et al. Biological activity of human-mouse IgG1, IgG2, IgG3, and IgG4 chimeric monoclonal antibodies with antitumor specificity. Proc. Natl Acad. Sci. USA 85, 4852–4856 (1988). · DOI
  23. Larsen, M. D. et al. Afucosylated IgG characterizes enveloped viral responses and correlates with COVID-19 severity. Science 371, eabc8378 (2021). · DOI · Paper page
  24. Bi, Y. et al. Distinct impact of IgG subclass on autoantibody pathogenicity in different IgG4-mediated diseases. eLife 11, e76223 (2022). · DOI
  25. Wilson, T. J., Fuchs, A. & Colonna, M. Cutting edge: human FcRL4 and FcRL5 are receptors for IgA and IgG. J. Immunol. 188, 4741–4745 (2012). · DOI
  26. Franco, A. et al. CD21 and FCRL5 form a receptor complex with robust B-cell activating capacity. Int. Immunol. 30, 569–578 (2018).
  27. van der Zee, J. S., van Swieten, P. & Aalberse, R. C. Inhibition of complement activation by IgG4 antibodies. Clin. Exp. Immunol. 64, 415–422 (1986).
  28. Tao, M. H., Smith, R. I. & Morrison, S. L. Structural features of human immunoglobulin G that determine isotype-specific differences in complement activation. J. Exp. Med. 178, 661–667 (1993). · DOI
  29. Davies, A. M. et al. Structural determinants of unique properties of human IgG4-Fc. J. Mol. Biol. 426, 630–644 (2014). This study reports the high-resolution crystal structure of human IgG4. · DOI
  30. Taylor, B. et al. C1q binding properties of monomer and polymer forms of mouse IgM μ-chain variants. Pro544Gly and Pro434Ala. J. Immunol. 153, 5303–5313 (1994). · DOI
  31. Smith, R. I., Coloma, M. J. & Morrison, S. L. Addition of a μ-tailpiece to IgG results in polymeric antibodies with enhanced effector functions including complement-mediated cytolysis by IgG4. J. Immunol. 154, 2226–2236 (1995). · DOI
  32. Diebolder, C. A. et al. Complement is activated by IgG hexamers assembled at the cell surface. Science 343, 1260–1263 (2014). · DOI
  33. Reinhard, L., Stahl, R. A. K. & Hoxha, E. Is primary membranous nephropathy a complement mediated disease? Mol. Immunol. 128, 195–204 (2020). · DOI
  34. Haddad, G. et al. Altered glycosylation of IgG4 promotes lectin complement pathway activation in anti-PLA2R1-associated membranous nephropathy. J. Clin. Invest. 131, e140453 (2021). · DOI
  35. Wei, B. et al. Fc galactosylation follows consecutive reaction kinetics and enhances immunoglobulin G hexamerization for complement activation. MAbs 13, 1893427 (2021). · DOI
  36. Li, Y., Yu, J., Wang, M., Cui, Z. & Zhao, M. H. Anti-phospholipase A2 receptor antibodies directly induced podocyte damage in vitro. Ren. Fail. 44, 304–313 (2022). · DOI
  37. Oskam, N. et al. Factors affecting IgG4-mediated complement activation. Front. Immunol. 14, 1087532 (2023). · DOI
  38. van der Zee, J. S., van Swieten, P. & Aalberse, R. C. Serologic aspects of IgG4 antibodies. II. IgG4 antibodies form small, nonprecipitating immune complexes due to functional monovalency. J. Immunol. 137, 3566–3571 (1986). · DOI
  39. Schuurman, J. et al. Normal human immunoglobulin G4 is bispecific: it has two different antigen-combining sites. Immunology 97, 693–698 (1999). · DOI
  40. Oostindie, S. C., Lazar, G. A., Schuurman, J. & Parren, P. Avidity in antibody effector functions and biotherapeutic drug design. Nat. Rev. Drug Discov. 21, 715–735 (2022). · DOI
  41. Clayton, F. et al. Eosinophilic esophagitis in adults is associated with IgG4 and not mediated by IgE. Gastroenterology 147, 602–609 (2014). · DOI
  42. Schuyler, A. J. et al. Specific IgG4 antibodies to cow’s milk proteins in pediatric patients with eosinophilic esophagitis. J. Allergy Clin. Immunol. 142, 139–148.e12 (2018). · DOI
  43. Platts-Mills, T. A. E. et al. An overview of the relevance of IgG4 antibodies in allergic disease with a focus on food allergens. Children 8, 418 (2021). · DOI
  44. Rispens, T., Ooijevaar-de Heer, P., Bende, O. & Aalberse, R. C. Mechanism of immunoglobulin G4 Fab-arm exchange. J. Am. Chem. Soc. 133, 10302–10311 (2011). · DOI
  45. Labrijn, A. F. et al. Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange. Proc. Natl Acad. Sci. USA 110, 5145–5150 (2013). This study describes a novel method that extrapolates the unique ability of IgG4 to exchange Fab-arms to create stable, bispecific IgG1 antibodies. · DOI
  46. Labrijn, A. F. et al. Species-specific determinants in the IgG CH3 domain enable Fab-arm exchange by affecting the noncovalent CH3–CH3 interaction strength. J. Immunol. 187, 3238–3246 (2011). · DOI
  47. Chen, Z. et al. Design of next-generation therapeutic IgG4 with improved manufacturability and bioanalytical characteristics. MAbs 12, 1829338 (2020). · DOI
  48. Konno, N. et al. Changes in N-glycans of IgG4 and its relationship with the existence of hypocomplementemia and individual organ involvement in patients with IgG4-related disease. PLoS ONE 13, e0196163 (2018). · DOI
  49. Culver, E. L. et al. Unique patterns of glycosylation in immunoglobulin subclass G4-related disease and primary sclerosing cholangitis. J. Gastroenterol. Hepatol. 34, 1878–1886 (2019). · DOI
  50. van de Bovenkamp, F. S., Hafkenscheid, L., Rispens, T. & Rombouts, Y. The emerging importance of IgG fab glycosylation in immunity. J. Immunol. 196, 1435–1441 (2016). · DOI
  51. van de Bovenkamp, F. S. et al. Adaptive antibody diversification through N-linked glycosylation of the immunoglobulin variable region. Proc. Natl Acad. Sci. USA 115, 1901–1906 (2018). · DOI
  52. Rombouts, Y. et al. Extensive glycosylation of ACPA-IgG variable domains modulates binding to citrullinated antigens in rheumatoid arthritis. Ann. Rheum. Dis. 75, 578–585 (2016). · DOI
  53. Lardinois, O. M. et al. Immunoglobulins G from patients with ANCA-associated vasculitis are atypically glycosylated in both the Fc and Fab regions and the relation to disease activity. PLoS ONE 14, e0213215 (2019). · DOI
  54. Koers, J. et al. Differences in IgG autoantibody Fab glycosylation across autoimmune diseases. J. Allergy Clin. Immunol. https://doi.org/10.1016/j.jaci.2022.10.035 (2023). · DOI
  55. Koers, J. et al. Biased N-glycosylation site distribution and acquisition across the antibody V region during B cell maturation. J. Immunol. 202, 2220–2228 (2019). · DOI
  56. Sabouri, Z. et al. Redemption of autoantibodies on anergic B cells by variable-region glycosylation and mutation away from self-reactivity. Proc. Natl Acad. Sci. USA 111, E2567–E2575 (2014). · DOI
  57. Kissel, T. et al. Surface Ig variable domain glycosylation affects autoantigen binding and acts as threshold for human autoreactive B cell activation. Sci. Adv. 8, eabm1759 (2022). · DOI
  58. Akdis, C. A. Therapies for allergic inflammation: refining strategies to induce tolerance. Nat. Med. 18, 736–749 (2012). · DOI
  59. Holgate, S. T. & Polosa, R. Treatment strategies for allergy and asthma. Nat. Rev. Immunol. 8, 218–230 (2008). · DOI
  60. Nouri-Aria, K. T. et al. Grass pollen immunotherapy induces mucosal and peripheral IL-10 responses and blocking IgG activity. J. Immunol. 172, 3252–3259 (2004). · DOI
  61. Eckl-Dorna, J. et al. Two years of treatment with the recombinant grass pollen allergy vaccine BM32 induces a continuously increasing allergen-specific IgG4 response. EBioMedicine 50, 421–432 (2019). · DOI
  62. Jones, S. M. et al. Clinical efficacy and immune regulation with peanut oral immunotherapy. J. Allergy Clin. Immunol. 124, 292–300.e1–e.97 (2009). · DOI
  63. Montalvao, S. A. et al. A longitudinal evaluation of anti-FVIII antibodies demonstrated IgG4 subclass is mainly correlated with high-titre inhibitor in haemophilia A patients. Haemophilia 21, 686–692 (2015). · DOI
  64. Akdis, M. & Akdis, C. A. Mechanisms of allergen-specific immunotherapy: multiple suppressor factors at work in immune tolerance to allergens. J. Allergy Clin. Immunol. 133, 621–631 (2014). · DOI
  65. Jutel, M. et al. Allergen-specific immunotherapy with recombinant grass pollen allergens. J. Allergy Clin. Immunol. 116, 608–613 (2005). · DOI
  66. Garcia, B. E., Sanz, M. L., Dieguez, I., de las Marinas, M. D. & Oehling, A. Modifications in IgG subclasses in the course of immunotherapy with grass pollen. J. Investig. Allergol. Clin. Immunol. 3, 19–25 (1993).
  67. James, L. K. et al. Long-term tolerance after allergen immunotherapy is accompanied by selective persistence of blocking antibodies. J. Allergy Clin. Immunol. 127, 509–516.e1–e5 (2011). · DOI
  68. Santos, A. F. et al. IgG4 inhibits peanut-induced basophil and mast cell activation in peanut-tolerant children sensitized to peanut major allergens. J. Allergy Clin. Immunol. 135, 1249–1256 (2015). · DOI
  69. Subbarayal, B. et al. Kinetics, cross-reactivity, and specificity of Bet v 1-specific IgG4 antibodies induced by immunotherapy with birch pollen. Allergy 68, 1377–1386 (2013). · DOI
  70. Meiler, F., Klunker, S., Zimmermann, M., Akdis, C. A. & Akdis, M. Distinct regulation of IgE, IgG4 and IgA by T regulatory cells and Toll-like receptors. Allergy 63, 1455–1463 (2008). · DOI
  71. Meiler, F. et al. In vivo switch to IL-10-secreting T regulatory cells in high dose allergen exposure. J. Exp. Med. 205, 2887–2898 (2008). · DOI · Paper page
  72. Kurniawan, A. et al. Differential expression of IgE and IgG4 specific antibody responses in asymptomatic and chronic human filariasis. J. Immunol. 150, 3941–3950 (1993). · DOI
  73. Turner, J. D. et al. Allergen-specific IgE and IgG4 are markers of resistance and susceptibility in a human intestinal nematode infection. Microbes Infect. 7, 990–996 (2005). · DOI
  74. Hussain, R., Poindexter, R. W. & Ottesen, E. A. Control of allergic reactivity in human filariasis. Predominant localization of blocking antibody to the IgG4 subclass. J. Immunol. 148, 2731–2737 (1992). · DOI
  75. Nkurunungi, G. et al. Do helminth infections underpin urban-rural differences in risk factors for allergy-related outcomes? Clin. Exp. Allergy 49, 663–676 (2019). · DOI
  76. Heiner, D. C. IgG4 immunodeficiency. N. Engl. Reg. Allergy Proc. 9, 43–50 (1988). · DOI
  77. Moss, R. B., Carmack, M. A. & Esrig, S. Deficiency of IgG4 in children: association of isolated IgG4 deficiency with recurrent respiratory tract infection. J. Pediatr. 120, 16–21 (1992). · DOI
  78. Koutroumpakis, F. et al. Serum IgG4 subclass deficiency defines a distinct, commonly encountered, severe inflammatory bowel disease subtype. Inflamm. Bowel Dis. 27, 855–863 (2021). · DOI
  79. Koneczny, I. Update on IgG4-mediated autoimmune diseases: new insights and new family members. Autoimmun. Rev. 19, 102646 (2020). This work presents a comprehensive review of IgG4-AIDs. · DOI
  80. Futei, Y. et al. Predominant IgG4 subclass in autoantibodies of pemphigus vulgaris and foliaceus. J. Dermatol. Sci. 26, 55–61 (2001). · DOI
  81. Huijbers, M. G. et al. Longitudinal epitope mapping in MuSK myasthenia gravis: implications for disease severity. J. Neuroimmunol. 291, 82–88 (2016). · DOI
  82. Huijbers, M. G. et al. MuSK IgG4 autoantibodies cause myasthenia gravis by inhibiting binding between MuSK and Lrp4. Proc. Natl Acad. Sci. USA 110, 20783–20788 (2013). · DOI
  83. Endmayr, V. et al. Anti-neuronal IgG4 autoimmune diseases and IgG4-related diseases may not be part of the same spectrum: a comparative study. Front. Immunol. 12, 785247 (2021). · DOI
  84. Funakoshi, T. et al. Enrichment of total serum IgG4 in patients with pemphigus. Br. J. Dermatol. 167, 1245–1253 (2012). · DOI
  85. Vergoossen, D. L. E. et al. Enrichment of serum IgG4 in MuSK myasthenia gravis patients. J. Neuroimmunol. 373, 577978 (2022). · DOI
  86. Panhuber, A. et al. A systematic review and meta-analysis of HLA class II associations in patients with IgG4 autoimmunity. Sci. Rep. 12, 9229 (2022). · DOI
  87. Bhol, K. C., Rojas, A. I., Khan, I. U. & Ahmed, A. R. Presence of interleukin 10 in the serum and blister fluid of patients with pemphigus vulgaris and pemphigoid. Cytokine 12, 1076–1083 (2000). · DOI
  88. Satyam, A., Khandpur, S., Sharma, V. K. & Sharma, A. Involvement of TH1/TH2 cytokines in the pathogenesis of autoimmune skin disease – pemphigus vulgaris. Immunol. Invest. 38, 498–509 (2009). · DOI
  89. Yilmaz, V. et al. Differential cytokine changes in patients with myasthenia gravis with antibodies against AChR and MuSK. PLoS ONE 10, e0123546 (2015). · DOI
  90. Westwood, J. P., Langley, K., Heelas, E., Machin, S. J. & Scully, M. Complement and cytokine response in acute thrombotic thrombocytopenic purpura. Br. J. Haematol. 164, 858–866 (2014). · DOI
  91. Li, N. et al. From insect bites to a skin autoimmune disease: a conceivable pathway to endemic pemphigus foliaceus. Front. Immunol. 13, 907424 (2022). · DOI
  92. Qian, Y. et al. Cutting edge: Brazilian pemphigus foliaceus anti-desmoglein 1 autoantibodies cross-react with sand fly salivary LJM11 antigen. J. Immunol. 189, 1535–1539 (2012). This study provides the first evidence for molecular mimicry as a cause of the IgG4-AID pemphigus foliaceus. · DOI
  93. Lin, L. et al. Walnut antigens can trigger autoantibody development in patients with pemphigus vulgaris through a “hit-and-run” mechanism. J. Allergy Clin. Immunol. 144, 720–728.e4 (2019). · DOI
  94. Doppler, K. et al. Anti-CNTN1 IgG3 induces acute conduction block and motor deficits in a passive transfer rat model. J. Neuroinflammation 16, 73 (2019). · DOI
  95. Huang, C. C. et al. IgG subclass staining in renal biopsies with membranous glomerulonephritis indicates subclass switch during disease progression. Mod. Pathol. 26, 799–805 (2013). · DOI
  96. Koneczny, I., Cossins, J., Waters, P., Beeson, D. & Vincent, A. MuSK myasthenia gravis IgG4 disrupts the interaction of LRP4 with MuSK but both IgG4 and IgG1–3 can disperse preformed agrin-independent AChR clusters. PLoS ONE 8, e80695 (2013). · DOI
  97. Joubert, B. et al. Characterization of a subtype of autoimmune encephalitis with anti-contactin-associated protein-like 2 antibodies in the cerebrospinal fluid, prominent limbic symptoms, and seizures. JAMA Neurol. 73, 1115–1124 (2016). · DOI
  98. Kornau, H. C. et al. Human cerebrospinal fluid monoclonal LGI1 autoantibodies increase neuronal excitability. Ann. Neurol. 87, 405–418 (2020). · DOI
  99. Sinkovits, G. et al. Concentration and subclass distribution of anti-ADAMTS13 IgG autoantibodies in different stages of acquired idiopathic thrombotic thrombocytopenic purpura. Front. Immunol. 9, 1646 (2018). · DOI
  100. Bhol, K., Mohimen, A. & Ahmed, A. R. Correlation of subclasses of IgG with disease activity in pemphigus vulgaris. Dermatology 189, 85–89 (1994). · DOI
  101. Daveau, M. et al. IgG4 subclass in malignant melanoma. J. Natl Cancer Inst. 58, 189–192 (1977). · DOI
  102. Karagiannis, P. et al. IgG4 subclass antibodies impair antitumor immunity in melanoma. J. Clin. Invest. 123, 1457–1474 (2013). This study provides evidence for IgG4+ B cells in the tumour microenvironment and the induction of IL-10 secretion by tumour cells, and shows how IgG4 can block endogenous antitumour immune responses. · DOI
  103. Crescioli, S. et al. IgG4 Characteristics and functions in cancer immunity. Curr. Allergy Asthma Rep. 16, 7 (2016). · DOI
  104. Jordakieva, G. et al. IgG4 induces tolerogenic M2-like macrophages and correlates with disease progression in colon cancer. Oncoimmunology 10, 1880687 (2021). · DOI
  105. Karagiannis, P. et al. Elevated IgG4 in patient circulation is associated with the risk of disease progression in melanoma. Oncoimmunology 4, e1032492 (2015). · DOI
  106. Gilbert, A. E. et al. Monitoring the systemic human memory B cell compartment of melanoma patients for anti-tumor IgG antibodies. PLoS ONE 6, e19330 (2011). · DOI
  107. van de Veen, W. et al. A novel proangiogenic B cell subset is increased in cancer and chronic inflammation. Sci. Adv. 6, eaaz3559 (2020). This study identifies a novel IgG4+ B cell subset that has pro-angiogenic features. · DOI
  108. Andersen, B. R. & Terry, W. D. γG4-globulin antibody causing inhibition of clotting factor 8. Nature 217, 174–175 (1968). This paper is the first description of acquired haemophilia A being caused by IgG4 autoantibodies to clotting factor FVIII. · DOI
  109. Hofbauer, C. J. et al. Affinity of FVIII-specific antibodies reveals major differences between neutralizing and nonneutralizing antibodies in humans. Blood 125, 1180–1188 (2015). · DOI
  110. Iizuka, A. & Nagao, T. Analysis of IgG heavy chain subclasses of alloantibodies to factor IX by crossed immunoelectrophoresis of factor IX using the intermediate gel technique. Br. J. Haematol. 53, 687–688 (1983). · DOI
  111. Whelan, S. F. et al. Distinct characteristics of antibody responses against factor VIII in healthy individuals and in different cohorts of hemophilia A patients. Blood 121, 1039–1048 (2013). · DOI
  112. Deisenhammer, F., Reindl, M. & Berger, T. Immunoglobulin subclasses in patients with neutralizing and nonneutralizing antibodies against IFN-β1b. J. Interferon Cytokine Res. 21, 167–171 (2001). · DOI
  113. van Schie, K. A. et al. The antibody response against human and chimeric anti-TNF therapeutic antibodies primarily targets the TNF binding region. Ann. Rheum. Dis. 74, 311–314 (2015). · DOI
  114. van Schouwenburg, P. A. et al. IgG4 production against adalimumab during long term treatment of RA patients. J. Clin. Immunol. 32, 1000–1006 (2012). · DOI
  115. Witmer, C. & Young, G. Factor VIII inhibitors in hemophilia A: rationale and latest evidence. Ther. Adv. Hematol. 4, 59–72 (2013). · DOI
  116. van Helden, P. M. et al. IgG subclasses of anti-FVIII antibodies during immune tolerance induction in patients with hemophilia A. Br. J. Haematol. 142, 644–652 (2008). · DOI
  117. Knobl, P. Prevention and management of bleeding episodes in patients with acquired hemophilia A. Drugs 78, 1861–1872 (2018). · DOI
  118. van Schouwenburg, P. A. et al. Functional analysis of the anti-adalimumab response using patient-derived monoclonal antibodies. J. Biol. Chem. 289, 34482–34488 (2014). · DOI
  119. Kamisawa, T. et al. A new clinicopathological entity of IgG4-related autoimmune disease. J. Gastroenterol. 38, 982–984 (2003). · DOI
  120. Kamisawa, T., Zen, Y., Pillai, S. & Stone, J. H. IgG4-related disease. Lancet 385, 1460–1471 (2015). · DOI
  121. Wallace, Z. S. et al. Plasmablasts as a biomarker for IgG4-related disease, independent of serum IgG4 concentrations. Ann. Rheum. Dis. 74, 190–195 (2015). · DOI
  122. Maillette de Buy Wenniger, L. J. et al. Immunoglobulin G4+ clones identified by next-generation sequencing dominate the B cell receptor repertoire in immunoglobulin G4 associated cholangitis. Hepatology 57, 2390–2398 (2013). · DOI
  123. Shiokawa, M. et al. Pathogenicity of IgG in patients with IgG4-related disease. Gut 65, 1322–1332 (2016). · DOI
  124. Lohr, J. M. et al. Autoantibodies against the exocrine pancreas in autoimmune pancreatitis: gene and protein expression profiling and immunoassays identify pancreatic enzymes as a major target of the inflammatory process. Am. J. Gastroenterol. 105, 2060–2071 (2010). · DOI
  125. Asada, M. et al. Identification of a novel autoantibody against pancreatic secretory trypsin inhibitor in patients with autoimmune pancreatitis. Pancreas 33, 20–26 (2006). · DOI
  126. Hubers, L. M. et al. Annexin A11 is targeted by IgG4 and IgG1 autoantibodies in IgG4-related disease. Gut 67, 728–735 (2018).
  127. Culver, E. L. et al. Increased IgG4 responses to multiple food and animal antigens indicate a polyclonal expansion and differentiation of pre-existing B cells in IgG4-related disease. Ann. Rheum. Dis. 74, 944–947 (2015). · DOI
  128. Liu, J. et al. Immune dysregulation in IgG4-related disease. Front. Immunol. 12, 738540 (2021). · DOI
  129. Culver, E. L. et al. Increases in IgE, eosinophils, and mast cells can be used in diagnosis and to predict relapse of IgG4-related disease. Clin. Gastroenterol. Hepatol. 15, 1444–1452.e6 (2017). · DOI
  130. Della Torre, E. et al. Prevalence of atopy, eosinophilia, and IgE elevation in IgG4-related disease. Allergy 69, 269–272 (2014). · DOI
  131. Khosroshahi, A., Bloch, D. B., Deshpande, V. & Stone, J. H. Rituximab therapy leads to rapid decline of serum IgG4 levels and prompt clinical improvement in IgG4-related systemic disease. Arthritis Rheum. 62, 1755–1762 (2010). · DOI
  132. Matza, M. A. et al. Abatacept in IgG4-related disease: a prospective, open-label, single-arm, single-centre, proof-of-concept study. Lancet Rheumatol. 4, e105–e112 (2022). · DOI
  133. Hirano, K. et al. Incidence of malignancies in patients with IgG4-related disease. Intern. Med. 53, 171–176 (2014). · DOI
  134. Tang, H. et al. Malignancy and IgG4-related disease: the incidence, related factors and prognosis from a prospective cohort study in China. Sci. Rep. 10, 4910 (2020). · DOI
  135. Wallace, Z. S. et al. IgG4-related disease: clinical and laboratory features in one hundred twenty-five patients. Arthritis Rheumatol. 67, 2466–2475 (2015). · DOI
  136. Kindle, S. A. et al. Dermatologic disorders in 118 patients with autoimmune (immunoglobulin G4-related) pancreatitis: a retrospective cohort analysis. Am. J. Clin. Dermatol. 16, 125–130 (2015). · DOI
  137. Raibagkar, P., Ferry, J. A. & Stone, J. H. Is MuSK myasthenia gravis linked to IgG4-related disease? J. Neuroimmunol. 305, 82–83 (2017). · DOI
  138. Labasque, M. et al. Specific contactin N-glycans are implicated in neurofascin binding and autoimmune targeting in peripheral neuropathies. J. Biol. Chem. 289, 7907–7918 (2014). · DOI
  139. Querol, L. et al. Neurofascin IgG4 antibodies in CIDP associate with disabling tremor and poor response to IVIg. Neurology 82, 879–886 (2014). · DOI
  140. Delmont, E. et al. Antibodies against the node of Ranvier: a real-life evaluation of incidence, clinical features and response to treatment based on a prospective analysis of 1500 sera. J. Neurol. 267, 3664–3672 (2020). · DOI
  141. Manso, C., Querol, L., Mekaouche, M., Illa, I. & Devaux, J. J. Contactin-1 IgG4 antibodies cause paranode dismantling and conduction defects. Brain 139, 1700–1712 (2016). · DOI
  142. Devaux, J. J. et al. Neurofascin-155 IgG4 in chronic inflammatory demyelinating polyneuropathy. Neurology 86, 800–807 (2016). · DOI
  143. Ogata, H. et al. Unique HLA haplotype associations in IgG4 anti-neurofascin 155 antibody-positive chronic inflammatory demyelinating polyneuropathy. J. Neuroimmunol. 339, 577139 (2020). · DOI
  144. Martin-Aguilar, L. et al. Clinical and laboratory features in anti-NF155 autoimmune nodopathy. Neurol. Neuroimmunol. Neuroinflamm. 9, e1098 (2022). · DOI
  145. Manso, C. et al. Anti-neurofascin-155 IgG4 antibodies prevent paranodal complex formation in vivo. J. Clin. Invest. 129, 2222–2236 (2019). · DOI
  146. Evoli, A. et al. Myasthenia gravis with antibodies to MuSK: an update. Ann. N. Y. Acad. Sci. 1412, 82–89 (2018). · DOI
  147. Klooster, R. et al. Muscle-specific kinase myasthenia gravis IgG4 autoantibodies cause severe neuromuscular junction dysfunction in mice. Brain 135, 1081–1101 (2012). · DOI
  148. Amagai, M. et al. Conformational epitopes of pemphigus antigens (Dsg1 and Dsg3) are calcium dependent and glycosylation independent. J. Invest. Dermatol. 105, 243–247 (1995). · DOI
  149. Yokouchi, M. et al. Pathogenic epitopes of autoantibodies in pemphigus reside in the amino-terminal adhesive region of desmogleins which are unmasked by proteolytic processing of prosequence. J. Invest. Dermatol. 129, 2156–2166 (2009). · DOI
  150. Sekiguchi, M. et al. Dominant autoimmune epitopes recognized by pemphigus antibodies map to the N-terminal adhesive region of desmogleins. J. Immunol. 167, 5439–5448 (2001). · DOI
  151. Kasperkiewicz, M. et al. Pemphigus. Nat. Rev. Dis. Prim. 3, 17026 (2017). · DOI
  152. Schaller, M., Vogel, M., Kentouche, K., Lammle, B. & Kremer Hovinga, J. A. The splenic autoimmune response to ADAMTS13 in thrombotic thrombocytopenic purpura contains recurrent antigen-binding CDR3 motifs. Blood 124, 3469–3479 (2014). · DOI
  153. Doyle, A. J. et al. Long-term risk of relapse in immune-mediated thrombotic thrombocytopenic purpura and the role of anti-CD20 therapy. Blood 141, 285–294 (2022). · DOI
  154. Kremer Hovinga, J. A. et al. Thrombotic thrombocytopenic purpura. Nat. Rev. Dis. Prim. 3, 17020 (2017). · DOI
  155. Xu, Z. et al. Immunoglobulin class-switch DNA recombination: induction, targeting and beyond. Nat. Rev. Immunol. 12, 517–531 (2012). · DOI
  156. Wagar, L. E. et al. Modeling human adaptive immune responses with tonsil organoids. Nat. Med. 27, 125–135 (2021). This study reports an in vitro model based on tonsil cell extracts that allows for the study of de novo human antibody responses, including IgG4. · DOI
  157. Cevhertas, L. et al. IL-10 induces IgG4 production in NOD-scid Il2rγnull mice humanized by engraftment of peripheral blood mononuclear cells. Allergy 76, 3525–3529 (2021). · DOI

Cited by

Sorted by citations

Metadata

Authors
Rispens, T., & Huijbers, M. G.
ORCID
Huijbers, Maartje G.
Venue
Nature Reviews Immunology
Publisher
Springer Science and Business Media LLC
Published
2023-04-24
Volume
23
Issue
11
Pages
763-778
ISSN
  • 1474-1733
  • 1474-1741
DOI
10.1038/s41577-023-00871-z
PMC
PMC10123589
Cited by
282
References
2
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review